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Abstract: With the recent approval of pazopanib, an oral multitargeted tyrosine kinase inhibitor 
which potently targets vascular endothelial growth factor receptors 1–3, platelet-derived growth 
factor, and c-kit, six agents are now available for use in the management of metastatic renal cell 
carcinoma (RCC). Pazopanib has shown improved progression-free survival compared with 
placebo in treatment-naïve or cytokine-treated patients with metastatic RCC in large Phase II 
and Phase III clinical trials. Pazopanib has demonstrated a tolerable side effect profile and is 
currently being compared with sunitinib in a Phase III noninferiority trial. In this review, the 
outcomes of the clinical testing of pazopanib are discussed, as well as a perspective on the 
placement of pazopanib among other approved agents.
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Introduction
The number of treatment options for the management of renal cell carcinoma (RCC) 
has been expanding rapidly. In fact, over the past five years, six new agents have been 
approved by the US Food and Drug Administration (FDA), markedly expanding the 
available options for the clinician. Unlike the previous standard of care, immune-based 
therapies,1 these new agents target key molecular pathways which are essential in the 
pathogenesis of RCC. One vital aspect of RCC molecular biology which has proved to 
be a very crucial target is that of tumor angiogenesis.2–4 RCC tumors are known to have a 
highly vascular phenotype, with vascular endothelial growth factor (VEGF) and its effects 
on the stromal environment playing an important role.5–7 Elevated VEGF is commonly 
noted in RCC patients,8 and is felt to be directly related to the functional loss of the von 
Hippel-Lindau protein which occurs in the majority of sporadic RCC cancers.9,10 The von 
Hippel-Lindau protein regulates hypoxia inducible factors 1 and 2 alpha which in turn are 
important transcription factors which promote a variety of genes which regulate tumor 
cell survival, proliferation, and spread.11 Several of these genes which are upregulated 
promote tumor angiogenesis, including VEGF, platelet-derived growth factor (PDGF), 
and angiopoeitin 2.10,12 Many of the new molecularly targeted agents which have been 
approved directly inhibit the ability of the RCC to utilize these proangiogenic pathways, 
such as VEGF and PDGF receptor tyrosine kinase inhibitors (TKIs).13
Approved agents which inhibit the VEGF and PDGF receptor tyrosine kinases are 
sunitinib, sorafenib, and, most recently, pazopanib. Bevacizumab, another improved 
agent, is a monoclonal antibody which binds the VEGF molecule. Another class of OncoTargets and Therapy 2010:3
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Figure 1 Key molecular pathways in renal cell carcinoma pathogenesis and the points at which the currently approved agents function. 
Abbreviations: HiF, hypoxia inducible factor; RCC, renal cell carcinoma; PDGF, platelet-derived growth factor; TK, tyrosine kinase; veGF, vascular endothelial growth factor; 
vHL, von Hippel-Lindau protein.
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molecularly targeted agents, the mTOR inhibitors, affects 
the von Hippel-Lindau protein/hypoxia inducible factor 
pathway at a separate point. mTOR is a protein which is 
important in regulating cell survival in “stress”   conditions, 
such as low nutrient or oxygen states. One manner in which 
mTOR can regulate response to these conditions is by 
upregulating hypoxia inducible factor protein   synthesis.14 
Currently, the available drugs which target mTOR are tem-
sirolimus and everolimus. Figure 1 illustrates the molecular 
targets of the currently approved drugs for the management 
of RCC.
With a variety of treatment options available to the 
oncologist, it is important to understand the clinical data 
behind each approved agent and use these data to guide thera-
peutic decision-making. This current review will describe the 
preclinical and clinical data involving pazopanib, the latest 
agent to be approved, with emphasis on this agent’s clinical 
development for RCC. Additionally, a synopsis of other 
approved agents for RCC will be given in order to help the 
reader understand the appropriate placement of pazopanib 
among the available drug options.
Preclinical analysis of pazopanib
Pazopanib (Votrient®, GW786034, [4-[2,3-dimethyl-2H-
indazole-6-yl methylamino]2-dypyrimidinyl amino-2methyl-
benzene sulfonamide]) is a novel multitargeted TKI synthesized 
by GlaxoSmithKline. The discovery of pazopanib is discussed 
elsewhere.15 By competitively binding to the adenosine 
triphosphate enzymatic pocket, pazopanib potently inhibits 
the function of several receptor tyrosine kinases, including 
VEGF receptors 1–3, PDGF receptor- α and -β, and c-kit.16 
Pazopanib also has modest activity against fibroblast growth 
factor receptors 1 and 3 and the c-fms receptor. Additionally, 
pazopanib inhibits 13 other kinases by at least 50%; however, 
only five of these kinases were inhibited with an IC50 within 
10-fold of VEGFR 2 activity (Aurora A, c-RAF, MLK-1, PTK5, 
and TAO3). Table 1 shows the IC50 inhibition concentrations 
for kinases clinically relevant to RCC for pazopanib and other 
similar agents either approved or in development. Although 
pazopanib does potently inhibit several targets, the range is 
somewhat narrower than sunitinib and sorafenib.
Pazopanib was found to have inhibitory activity in a 
variety of human xenografts in preclinical development.16 OncoTargets and Therapy 2010:3
Table 1 Kinase inhibitory concentrations (iC50, nmol) for multitargeted tyrosine kinase inhibitors for renal cell carcinoma (includes 
tivozanib and axitinib which are in Phase iii study, but not yet approved) arranged in order of veGFR2 potency
Drug VEGFR1 VEGFR2 VEGFR3 PDGF-α PDGF-β c-kit Flt-3 RAF
Tivozanib36 0.21 0.16 0.24 – 1.72 1.63 – –
Axitinib37 0.1 0.2 0.1–0.3 5 1.6 1.7 .1000 –
Sunitinib38 2 10 17 5–10 10 13 1–10 –
Pazopanib16 10 30 47 71 84 74 .2000 –
Sorafenib39 – 90 20 50–60 50–60 68 46 5–10
Abbreviations: PDGF, platelet-derived growth factor; veGFR, vascular endothelial growth factor receptor.
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The greatest activity was seen in RCC (Caki-2),   colorectal 
(HT29), and non-small cell lung cancer (NCI-H322) 
xenografts. Of these three tumor types, RCC was the most 
  sensitive to treatment with pazopanib. More modest activity 
was seen in melanoma (A375p), prostate adenocarcinoma 
(PC3), and breast adenocarcinoma (BT474) xenograft 
  models. Pazopanib was also shown to inhibit angiogenic 
activity mediated by VEGF and fibroblast growth factor in 
two mouse models of angiogenesis.16 Of note, pazopanib has 
been and is currently being evaluated for clinical efficacy 
in several different tumor types, including breast, cervical, 
hepatocellular, sarcoma, colorectal, non-small cell lung 
  cancer, malignant glioma, thyroid, and ovarian cancer.
Phase I analysis of pazopanib  
in advanced solid tumors
A Phase I study of pazopanib in patients with advanced 
stage solid tumors whose cancer was refractory to standard 
therapy was conducted in order to determine the appropriate 
dosing and safety profile of the agent. In this multicenter, 
open-label, nonrandomized study, 63 patients were enrolled, 
with 43 being enrolled to a dose escalation study and 20 
evaluated in a dose expansion study.17 Patients were required 
to have histologically confirmed advanced solid tumors, 
adequate performance status and laboratory parameters, and 
a life expectancy of $12 weeks. The dosing arms that were 
studied included ranges of 50–100 mg three times weekly, 
50–2000 mg daily, and 300–400 mg daily. The optimal 
dosing regimen was found to be 800 mg daily. Although no 
maximally tolerated dose was found in this study, a steady-
state exposure plateau was reached at the dose of 800 mg 
daily. Pharmacokinetic analysis showed that the mean half-
life of pazopanib was approximately 31 hours. Common 
drug-related events included hypertension, diarrhea, hair 
depigmentation, and nausea.
Interestingly, 14 patients obtained some clinical benefit 
from pazopanib as deemed by either durable ($six months) 
stable disease or partial response. Three patients obtained 
a partial response in the study, including two RCC patients 
and one patient with a pancreatic neuroendocrine tumor. 
Correlative assessments within the study included dynamic 
contrast enhanced magnetic resonance imaging in 12 patients. 
Seven of the 12 patients had a substantial ($50%) reduction 
in tumor blood flow after eight days of pazopanib exposure. 
Ten patients had a $50% reduction in tumor blood flow by 
day 22.
Phase II trial in advanced  
RCC patients
In order to evaluate further the efficacy of pazopanib and 
explore potential toxicities in patients with advanced/
metastatic RCC, a multicenter, randomized, discontinuation 
study was conducted.18 Patients with metastatic or locally 
recurrent clear cell RCC (predominantly clear cell features 
on histology), were either treatment-naïve or treated with 
cytokine therapy, and who had measurable disease defined 
by Response Evaluation Criteria In Solid Tumors (RECIST) 
were included in this study. In this open-label trial, pazopanib 
800 mg/day was administered orally. The trial was initially 
designed as a randomized discontinuation study, with all 
patients receiving pazopanib and those with stable disease 
randomized to receive either continued drug or matched 
placebo. However, planned interim analysis conducted after 
the first 60 patients had reached 12 weeks, showed that the 
response rate was 38% and therefore further randomization 
was halted and all patients were assigned to pazopanib.
This Phase II study enrolled 225 eligible patients, with 
55 patients having stable disease at week 12 and undergo-
ing randomization. The overall response rate for patients 
treated with pazopanib was 35%, and response rates were 
similar whether patients were treatment-naïve or cytokine-
pretreated. The median duration of response was found to 
be 68 weeks and the median progression-free survival (PFS) 
was 52 weeks (95% confidence interval [CI] 44–60 weeks). 
The most common adverse effects included fatigue, nausea, 
hair depigmentation, and hypertension. The most common OncoTargets and Therapy 2010:3
Table 2 Toxicities of pazopanib from the Phase iii study in renal 
cell carcinoma (n = 290) which occurred at a rate of 10% or 
more. The toxicities are arranged in order of the most common 
adverse (any grade) to the least common. Grade 3/4 toxicities 
with frequency of occurrence are listed as well
Adverse events Any grade Grade 3/4
Number % Number %
ALT elevation 152 53 35 12
AST elevation  152 53 23 8
Diarrhea  150 52 11 4
Hypertension  115 40 13 4
Hyperglycemia  115 41  2 1
Hair depigmentation  109 38  1 0
Leukopenia  103 37  0 0
Total bilirubin elevation 102 36  9 3
Hypophosphatemia  95 34 11 4
Neutropenia  94 34  4 1
Hypocalcemia  91 33  8 3
Thrombocytopenia  89 32  3 1
Hyponatremia  86 31 15 5
Lymphocytopenia  86 31 12 4
Nausea  74 26  2 1
Anorexia  65 22  6 2
vomiting  61 21  7 2
Fatigue  55 19  7 2
Hypoglycemia  47 17  1 0
Asthenia  41 14  8 3
Abdominal pain  32 11  6 2
Hypomagnesemia  31 11  9 3
Headache  30 10  0 0
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
150
Cowey et al
laboratory adverse events included elevation of alanine 
aminotransferase and aspartate aminotransferase. Grade 3 
or 4 adverse events included hypertension, transaminase 
  elevation, diarrhea, and fatigue. Dose reduction was per-
formed in 31% of patients (dose level 1 was 400 mg daily) 
and 50% of these patients were able to increase back up to 
the target dose. Based on these efficacy and safety data, a 
large Phase III trial of pazopanib in advanced RCC patients 
was performed.
Phase III study of pazopanib  
in advanced RCC patients
A Phase III multicenter, international, randomized, placebo-
controlled study of pazopanib in patients with advanced/ 
metastatic RCC patients has been conducted and recently 
reported.19 Enrollment criteria for this study was similar to 
those in the Phase II study, with patients having clear cell or 
predominantly clear cell morphology and either treatment-
naïve or a single prior cytokine-based therapy being eligible for 
participation. Patients were stratified by Eastern Cooperative 
Oncology Group (ECOG) performance status (0 versus 1), 
prior nephrectomy, and prior treatment (naïve versus cytokine). 
Patients were randomized 2:1 to receive either pazopanib or 
matching placebo. Patients randomized to the study drug 
arm received pazopanib 800 mg/day orally. The primary 
endpoint of the study was PFS, with secondary endpoints 
including overall survival, overall response rate, and safety. 
Additionally quality of life analyses were performed. In this 
study 435 patients were randomized (290 pazopanib versus 
145 placebo). Most of these patients had previously undergone 
nephrectomy (88%) and were treatment-naïve (54%).
The median PFS was found to be 9.2 months versus 
4.2 months in the treatment group compared with placebo with 
a hazards ratio (HR) of 0.46 (95% CI 0.34–0.62, P , 0.0001). 
When analyzed based on prior therapy, the median PFS 
for patients who were treatment-naïve was 11.1 months 
(versus 2.8 months for placebo, HR 0.40, P , 0.0001) com-
pared with 7.4 months in those that were cytokine-pretreated 
(versus 4.3 months for placebo, HR 0.54, P , 0.001). The 
overall response rate for the pazopanib-treated group was 
30% (95% CI 25.1%–35.6%) based on independent review. 
The treatment-naïve subset had an overall response rate of 
32% compared with 29% for the cytokine-treated subset. 
The median   duration of response was found to be 58.7 weeks. 
At the time of publication, overall survival data were not 
reported due to lack of maturity.
Adverse events were similar to that seen in the Phase I 
and II trials, with the most common adverse events being 
  diarrhea, hypertension, hair depigmentation,   nausea, 
anorexia, and vomiting (see Table 2). Of note, most adverse 
events were Grade 1 or 2. Grade 3 and 4 adverse events 
were seen in the pazopanib-treated group with a frequency 
of 33% and 7%, respectively, compared with the placebo 
group with a frequency of 14% and 6%, respectively. 
The most common Grade 3 or 4 adverse events in the 
pazopanib group were hypertension (4%) and diarrhea 
(4%). Of note, arterial thrombotic events were seen in 3% 
of the pazopanib-treated patients (myocardial infarction 
2%, cerebrovascular events ,1%, and transient ischemic 
attacks ,1%) compared with none in the placebo arm. In 
terms of laboratory abnormalities, most were Grade 1 or 2, 
with the most common being alanine aminotransferase 
or aspartate aminotransferase elevation. A quality of life 
assessment was also included in this trial and, interestingly, 
pazopanib was found to show no difference in terms of 
tolerability compared with placebo.
Based on the safety and efficacy of pazopanib in this 
clinical trial, pazopanib was approved for use in advanced 
RCC patients by the FDA in October 2010.OncoTargets and Therapy 2010:3
Table 3 Results from Phase iii trials of currently approved agents for the treatment of renal cell carcinoma 
Study agent Class Comparator Setting Primary outcome Overall survival 
benefit
Sorafenib veGF TKi Placebo Cytokine-pretreated improved PFS 
(5.5 versus 2.8 months)
No
Sunitinib veGF TKi interferon Treatment-naïve improved PFS 
(11 versus 5 months)
No
Temsirolimus mTOR inhibitor interferon Treatment-naïve improved OS (10.9 
versus 7.3 months) 
Yes
everolimus mTOR inhibitor Placebo Prior TKi improved PFS 
(4.9 versus 1.9 months)
No
Bevacizumab-interferon Monoclonal 
antibody to veGF
interferon Treatment-naïve improved PFS 
(AvOReN, 10.2 versus 
5.4 months; CALGB, 
8.5 versus 5.2 months)
No
Pazopanib veGF TKi Placebo Treatment-naïve or 
cytokine-pretreated
improved PFS 
(9.2 versus 4.2 months)
Data immature
Abbreviations: CALGB, Cancer and Leukemia Group B; veGF, vascular endothelial growth factor; TKi, tyrosine kinase inhibitor; PFS, progression-free survival; 
OS, overall survival.
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Placement of pazopanib among 
other available treatment options
Pazopanib is the latest addition to the armamentarium of 
therapies for metastatic RCC, making a total of six new 
treatment options in the past four years. Because of the many 
options which are available to the practitioner, it is help-
ful to understand the manner in which each of these drugs 
was evaluated in the clinical trial setting. Additionally, it is 
important to consider potential side effects of the drugs when 
determining appropriate therapy for each individual patient. 
A summary of pivotal Phase III data is shown in Table 3.
Sorafenib, a multitargeted TKI, was the first agent to 
gain approval in December 2005. Sorafenib potently inhib-
its VEGFR 1–3, PDGFR-α and -β, RAF, FLT-3, and c-kit. 
Sorafenib was compared with placebo in a Phase III ran-
domized trial in metastatic RCC patients previously treated 
with cytokine therapy and was demonstrated to have a PFS 
of 5.5 months compared with 2.8 months for placebo.20 
Common adverse events were fatigue, diarrhea, rash, and 
hand-foot syndrome. In a Phase II analysis of sorafenib to 
interferon in the treatment-naïve setting a similar PFS was 
seen (5.7 versus 5.6 months). Improvements in response rate 
and quality of life outcomes were noted in the group receiving 
sorafenib. Given the findings from the Phase III trial, there 
is Level 1 evidence for the use of sorafenib after cytokine 
therapy, although sorafenib is commonly employed as at least 
second-line therapy following initial sunitinib failure.
Sunitinib, a multitargeted TKI which inhibits VEGFR1-3, 
PDGFR-α and -β, FLT-3, and c-kit, gained approval in 
  January 2006 after results of a Phase III trial in treatment-naïve 
metastatic RCC patients showed a PFS of 11 months versus 
only 5 months for placebo.21 Response rates for sunitinib were 
31% compared with 6% for placebo. Common side effects 
included diarrhea, fatigue, nausea, hypertension, and hand-
foot syndrome. No overall survival advantage was seen in the 
sunitinib arm, which was attributed to the high rate of cross-
over or subsequent treatment with targeted therapies for those 
patients progressing on the interferon arm.22 Sunitinib has 
become the most commonly employed agent in the first-line 
treatment of RCC due to the findings of this pivotal trial.
Temsirolimus which inhibits mTOR was approved in May 
2007 for metastatic RCC after a Phase III trial in patients with 
metastatic RCC and poor risk features showed benefit com-
pared with interferon in the first-line setting.23 This three-armed 
trial evaluated temsirolimus as a single agent versus interferon 
versus an arm using a combination of the two agents. An over-
all survival benefit was seen in the temsirolimus group, with 
a median survival of 10.9 months compared with 7.3 months 
in the interferon group. There was no advantage seen in the 
combination arm. Adverse events commonly attributed to 
temsirolimus include fatigue, anemia, hyperlipidemia, and 
hyperglycemia. Due to these findings, temsirolimus is seen as 
a reasonable first-line option for patients with poor risk factors 
as defined by the Motzer criteria.24
Everolimus, an orally bioavailable mTOR inhibitor which 
acts in a similar fashion as temsirolimus, was studied in a 
population of metastatic RCC patients who had progressed 
on sunitinib, sorafenib, or both, and was approved after 
showing improved PFS in this population compared with 
placebo (4.9 versus 1.9 months).25,26 The side effect profile of 
everolimus is similar to that of temsirolimus, with common 
adverse events including fatigue, rash, stomatitis, anemia, OncoTargets and Therapy 2010:3
Table 4 Level 1 evidence for use of molecularly targeted agents in 
renal cell carcinoma showing potential treatment settings and agents 
which have a high level of clinical evidence supporting their use
Treatment setting Agents with high 
level of evidence 
Treatment-naïve, good- or intermediate-risk Sunitinib
Bevacizumab-interferon
pazopanib
Treatment-naïve, poor-risk Temsirolimus
Cytokine-refractory Sorafenib
pazopanib
Prior veGF inhibitor or veGF-refractory everolimus
Prior mTOR inhibitor ?
Abbreviation: veGF, vascular endothelial growth factor.
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hyperlipidemia, and hyperglycemia. Of note, a noninfec-
tious pneumonitis was seen in 8% of patients, with Grade 3 
pneumonitis in 3%. This toxicity is felt to be a unique mTOR 
inhibitor class effect. This is the first Phase III trial showing 
benefit following TKI failure and should be considered an 
option for patients who have become TKI-refractory.
Finally, bevacizumab was approved in combina-
tion with interferon after two Phase III studies showed 
that the combination was superior to interferon alone in 
  treatment-naïve metastatic RCC patients.27,28 In AVOREN, a 
Phase III study in treatment-naïve patients, patients receiving 
  bevacizumab-interferon therapy had an improved PFS com-
pared with interferon alone (10.2 months versus 5.4 months). 
Overall survival from this trial was recently reported and 
showed no statistically improved survival for the bevaci-
zumab arm.29 This effect has been similarly attributed to the 
addition of more effective therapy to the interferon arm upon 
progression. A Phase III Cancer and Leukemia Group B 
(CALGB) study in patients with similar disease also showed 
improvement in PFS for the combination arm (8.5 months 
versus 5.2 months). Common side effects of the bevacizumab 
  combination included fatigue, hypertension, and proteinuria.
Table 4 shows placement of the agents according to 
Level 1 evidence. Based on the previously mentioned 
Phase III studies, agents which have a high level of evi-
dence for use in good- or intermediate-risk metastatic RCC 
patients in the treatment-naïve setting would be sunitinib, 
bevacizumab-interferon, and pazopanib. In patients with 
poor-risk features, temsirolimus is the only agent to show 
survival benefit in the front-line setting. For patients who 
have received prior cytokine therapy, sorafenib or pazopanib 
have similar high level evidence. In patients who have pro-
gressed on TKIs, everolimus has shown benefit. Although 
these trials give the clinical practitioner a basic framework for 
how to consider use of these agents in the practical setting, 
our understanding of the optimal sequence of these therapies 
remains limited. However, a variety of clinical trials are being 
conducted which will expand our knowledge on optimal 
sequences and combinations of these therapies.
One important Phase III clinical trial which has recently 
closed to accrual is a front-line study which is randomizing 
metastatic RCC patients to either pazopanib or sunitinib. For 
the past four years, sunitinib has been the standard first-line 
option for metastatic RCC patients. However, with similar 
PFS outcomes in Phase II and III studies as that seen with 
sunitinib, this international, multicenter trial is designed 
to show that pazopanib is not inferior to sunitinib. If the 
primary endpoint of PFS is similar in this trial, then the 
secondary endpoints of toxicity and quality of life may help 
identify which of these agents should be considered the 
optimal first-line choice.
Role of pazopanib  
in the adjuvant setting
Several international, multicenter, randomized studies are 
currently being conducted evaluating the role of VEGF 
receptor TKIs in the adjuvant setting. Due to the increasing 
risk of incurable recurrence with increasing tumor stage,30,31 
the incorporation of an effective adjuvant systemic therapy 
following surgical resection has been a long sought-after 
goal. Prior efforts to improve recurrence risk following 
surgical resection involved the use of cytokine-based adju-
vant treatments and this approach was unsuccessful.32,33 
Currently, three studies evaluating VEGF-targeted adjuvant 
treatments are being conducted. The ASSURE (Adjuvant 
Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) 
trial is a randomized cooperative group study evaluating the 
adjuvant use of sorafenib or sunitinib versus placebo in RCC 
patients after they have undergone resection of localized 
disease (clear cell or non-clear cell allowed). The primary 
endpoint of this study is disease-free survival. The S-TRAC 
(Sunitinib Treatment of Renal Adjuvant Cancer) trial is a 
two-armed trial comparing one year of sunitinib therapy 
versus placebo in patients with resected localized clear 
cell RCC. Finally, in a similar manner, the SORCE trial 
(a Phase III randomized double-blind study comparing 
SOrafenib with placebo in patients with Resected primary 
renal CEll carcinoma) is currently comparing adjuvant 
sorafenib for one year versus sorafenib for three years versus 
matching placebos in patients with resected clear cell RCC 
or non-clear cell RCC. Everolimus will also be explored in 
the adjuvant setting versus placebo in a Southwest   Oncology 
Group trial.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Pazopanib’s role as an adjuvant therapy following 
  nephrectomy will also be explored in a Phase III randomized 
trial. In this trial, approximately 1500 patients with Stage 
T2 (Grade 3 or 4), T3, T4, or TxN1 clear cell RCC will 
undergo randomization to either pazopanib versus placebo 
following surgical resection. Pazopanib 800 mg daily will be 
administered for one year in the treatment arm. The primary 
endpoint will be recurrence-free survival, with the secondary 
endpoints including overall survival.
Role of pazopanib in sequential  
or combination therapy
Sequential therapy
During the course of first-line VEGF-targeted therapy, the 
RCC tumor will eventually become resistant to treatment, 
requiring a switch to a different agent. With the currently 
available options, this second-line treatment consists of either 
a different VEGF-targeted therapy or an mTOR inhibitor. 
A large amount of data has been collected showing that cross-
resistance is uncommon with sunitinib and sorafenib used in 
a sequential manner. Similarly, sunitinib has shown activity 
after bevacizumab and axitinib (a potent VEGF receptor 
inhibitor and TKI) and in sorafenib-treated RCC patients.34 
Additionally, everolimus was approved based on its activity 
in patients who had failed one or two VEGF-targeted TKIs. 
Unfortunately, no data exist which establish what the opti-
mal sequence of therapies should be, and it may be that the 
best sequencing of regimens will differ among the spectrum 
of RCC patients as we learn more about potential biologic 
subsets within this population.
Currently, several large clinical trials are ongoing 
which will evaluate therapeutic sequencing. The Phase III 
RECORD (REnal Cell cancer treatment with Oral RAD001 
given Daily)-3 trial will evaluate the sequence of sunitinib 
followed by everolimus versus everolimus followed by suni-
tinib. Another trial which has recently completed accrual is 
the AXIS trial, which is exploring the second-line efficacy of 
sorafenib versus axitinib following failure of prior sunitinib or 
mTOR inhibitor. The temsirolimus (Torisel®) 404 will deter-
mine the superiority of temsirolimus or sorafenib after first-
line TKI failure. In terms of pazopanib, it is currently being 
evaluated as a second-line agent in a single-institution Phase II 
trial (NCT00731211) in RCC patients who have failed either 
sunitinib or bevacizumab in the first-line setting.
Combination therapy
Although there is a rationale for combining targeted agents 
in the hope of producing improved outcomes, it is unclear 
if this approach is superior than sequential single agent 
  therapies. Attempts to combine sunitinib with bevacizumab 
or temsirolimus have resulted in too much toxicity. However, 
given pazopanib’s side effect profile, perhaps it will be more 
amenable to attempts at combination. Several trials are cur-
rently evaluating combination regimens. These include the 
RECORD-2 trial which is evaluating bevacizumab-interferon 
versus bevacizumab-everolimus. Similarly, the INTO-
RACT (INvestigation of TORisel and Avastin Combination 
  Therapy) trial is comparing bevacizumab-interferon versus 
  bevacizumab-temsirolimus. In a more complex four-armed 
study, the BeST trial (ECOG 2804) is evaluating bevacizumab 
alone   versus bevacizumab-temsirolimus, bevacizumab-
sorafenib, and sorafenib-temsirolimus. Pazopanib is   currently 
being evaluated in a single institution Phase II study in 
  combination with bevacizumab (NCT00992121), with end-
points focused on tumor response and pharmacodynamic 
correlates. Pazopanib is also being evaluated in a variety of 
  different tumor types in combination with a variety of different 
agents, such as ixabepilone, lapatinib, liposomal doxorubicin, 
  paclitaxel, temsirolimus, gemcitabine, and navelbine.
Conclusion
Pazopanib is an orally bioavailable multitargeted TKI which 
targets and potently inhibits VEGF-R1-3, PDGFR-α and -β, 
and c-kit. Based on its preclinical activity in RCC models, 
it was tested in a Phase I trial and showed tolerability with 
optimal dosing at 800 mg daily. Additionally, it has shown 
clinical efficacy for patients with metastatic clear cell RCC 
in large Phase II and Phase III clinical trials compared with 
placebo. Based on these studies, pazopanib was approved for 
use in metastatic RCC in October 2009.
Pazopanib is felt to have a favorable toxicity profile with 
apparently less common development of hand-foot syndrome 
and cytopenia compared with its predecessors. The lack of 
difference in quality of life assessment between patients tak-
ing pazopanib and placebo highlights this favorable toxicity 
profile. One potential explanation for the lack of cytopenia 
is that pazopanib is not a potent inhibitor of Flt-3. Addition-
ally, pazopanib appears to have a higher frequency of liver 
enzyme elevation, although this side effect was shown to 
be manageable in study patients. In a recent publication, 
an exploratory analysis of patients in both the Phase II and 
Phase III RCC trials was conducted to explore this side effect 
of pazopanib further. In this analysis, in those patients with 
hyperbilirubinemia (.1.5 × upper limit of normal), 84% 
had genetic polymorphisms consistent with homozygous or 
heterozygous Gilbert’s syndrome.35OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Based on cross-comparison of the Phase III trials 
  involving sunitinib and bevacizumab, pazopanib showed a 
similar degree of response and PFS. Currently, a large mul-
ticenter Phase III trial comparing sunitinib with pazopanib 
in treatment-naïve patients is ongoing, and should shed light 
on the potential equivalence of pazopanib and sunitinib. 
Pazopanib will also be evaluated in the adjuvant setting 
following surgical resection of localized RCC. Key questions 
regarding the proper sequence of targeted agents and the 
role of combinations of targeted agents still exist. Currently, 
pazopanib is considered a valid treatment option for meta-
static RCC patients in need of front-line therapy based on a 
high level of clinical evidence. The role which pazopanib will 
play in sequencing or combination regimens or in the   adjuvant 
setting, however, still needs to be further explored.
Disclosure
Dr. Sonpavde is a speaker for, and has received honoraria 
from, GSK.
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